TY - JOUR T1 - Combined Utility of 25 Disease and Risk Factor Polygenic Risk Scores for Stratifying Risk of All-Cause Mortality JF - medRxiv DO - 10.1101/2020.03.13.20035527 SP - 2020.03.13.20035527 AU - Allison Meisner AU - Prosenjit Kundu AU - Yan Dora Zhang AU - Lauren V. Lan AU - Sungwon Kim AU - Disha Ghandwani AU - Parichoy Pal Choudhury AU - Sonja I. Berndt AU - Neal D. Freedman AU - Montserrat Garcia-Closas AU - Nilanjan Chatterjee Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/14/2020.03.13.20035527.abstract N2 - While genome-wide association studies have identified susceptibility variants for numerous traits, their combined utility for predicting broad measures of health, such as mortality, remains poorly understood. We used data from the UK Biobank to combine polygenic risk scores (PRS) for 13 diseases and 12 mortality risk factors into sex-specific composite PRS (cPRS). These cPRS were moderately associated with all-cause mortality in independent data within the UK Biobank: the estimated hazard ratios per standard deviation were 1.10 (95% confidence interval: 1.05, 1.16) and 1.15 (1.10, 1.19) for women and men, respectively. Differences in life expectancy between the top and bottom 5% of the cPRS were estimated to be 4.79 (1.76, 7.81) years and 6.75 (4.16, 9.35) years for women and men, respectively. These associations were substantially attenuated after adjusting for non-genetic mortality risk factors measured at study entry (i.e., middle age for most participants). The cPRS may be useful in counseling younger individuals at higher genetic risk of mortality on modification of non-genetic factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Patient-Centered Outcomes Research Institute (grant number ME-1602-34530); the National Institutes of Health (1 R01 HG010480-01); and the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used are available from the UK Biobank upon request. https://www.ukbiobank.ac.uk ER -